📊 VIR Key Takeaways
Is Vir Biotechnology, Inc. (VIR) a Good Investment?
Vir Biotechnology exhibits critical operational deficiencies with negative revenue, -$132M operating cash burn, and no clear path to profitability despite an adequate cash reserve of $274M. While the balance sheet is fortress-like with zero debt and strong liquidity, the unsustainable cash burn rate (approximately $132M quarterly) provides only 2 years of runway, and deteriorating fundamentals outweigh balance sheet strength. The negative revenue figure raises data quality concerns but the underlying operational losses and negative cash conversion are authentic warning signs.
Vir Biotechnology, Inc. Key Strengths (VIR)
- Strong balance sheet with $274.2M cash and zero long-term debt
- Excellent liquidity position (7.11x current and quick ratios)
- Substantial asset base ($1.0B) provides operational foundation
- Improving loss trends year-over-year (net income improved 16.1%, EPS improved 17.5%)
VIR Stock Risks: Vir Biotechnology, Inc. Investment Risks
- Negative revenue (-$29.0K) indicates potential data quality issues or fundamental business problems
- Operating cash burn of -$132.4M quarterly is unsustainable without revenue generation or capital raise
- No visibility into product pipeline success probability or time to profitability from SEC data alone
- Negative ROE (-15.5%) and ROA (-12.3%) confirm shareholder value destruction
- Cash runway of ~2 years at current burn rate requires successful pipeline advancement
Key Metrics to Watch
- Quarterly revenue trends and achievement of commercial milestones
- Operating cash flow burn rate and runway duration
- Progress on pipeline programs and clinical trial advancement
- Capital raise activity and dilution impact on equity
Vir Biotechnology, Inc. (VIR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 457,848.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 7.11x current ratio provides a solid financial cushion.
VIR Profit Margin, ROE & Profitability Analysis
VIR vs Healthcare Sector: How Vir Biotechnology, Inc. Compares
How Vir Biotechnology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vir Biotechnology, Inc. Stock Overvalued? VIR Valuation Analysis 2026
Based on fundamental analysis, Vir Biotechnology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vir Biotechnology, Inc. Balance Sheet: VIR Debt, Cash & Liquidity
VIR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vir Biotechnology, Inc.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-4.59 indicates the company is currently unprofitable.
VIR Revenue Growth, EPS Growth & YoY Performance
VIR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $240.0K | -$163.1M | $-1.17 |
| Q2 2025 | $1.2M | -$111.0M | $-0.80 |
| Q1 2025 | $3.0M | -$65.3M | $-0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vir Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
VIR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vir Biotechnology, Inc. (CIK: 0001706431)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 2, 2026 | 4 | xslF345X06/wk-form4_1780436119.xml | View → |
| Jun 2, 2026 | 4 | xslF345X06/wk-form4_1780435911.xml | View → |
| May 28, 2026 | 4 | xslF345X06/wk-form4_1780010743.xml | View → |
| May 28, 2026 | 4 | xslF345X06/wk-form4_1780010721.xml | View → |
| May 28, 2026 | 4 | xslF345X06/wk-form4_1780010697.xml | View → |
❓ Frequently Asked Questions about VIR
What is the AI rating for VIR?
Vir Biotechnology, Inc. (VIR) has an AI grade of C with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VIR's key strengths?
Claude: Strong balance sheet with $274.2M cash and zero long-term debt. Excellent liquidity position (7.11x current and quick ratios).
What are the risks of investing in VIR?
Claude: Negative revenue (-$29.0K) indicates potential data quality issues or fundamental business problems. Operating cash burn of -$132.4M quarterly is unsustainable without revenue generation or capital raise.
What is VIR's revenue and growth?
Vir Biotechnology, Inc. reported revenue of $-29.0K.
Does VIR pay dividends?
Vir Biotechnology, Inc. does not currently pay dividends.
Where can I find VIR SEC filings?
Official SEC filings for Vir Biotechnology, Inc. (CIK: 0001706431) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VIR's EPS?
Vir Biotechnology, Inc. has a diluted EPS of $-0.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VIR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vir Biotechnology, Inc. has a C grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VIR stock overvalued or undervalued?
Valuation metrics for VIR: ROE of -15.5% (sector avg: 15%), net margin of 433,431.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VIR's AI grade for 2026?
Our dual AI analysis gives Vir Biotechnology, Inc. a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is VIR's free cash flow?
Vir Biotechnology, Inc.'s operating cash flow is $-132.4M, with capital expenditures of $390.0K. FCF margin is 457,848.3%.
How does VIR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 433,431.0% (avg: 12%), ROE -15.5% (avg: 15%), current ratio 7.11 (avg: 2).